Anne E. de Papp - Concepedia

Author

Anne E. de Papp

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

A E de Papp, A. E. de Papp, A.E. De Papp, A.E. de Papp, ANNE E. DE PAPP, ANNE E. de PAPP, Anne E de Papp, Anne E. De Papp, Anne E. de Papp

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)United States Military Academy University of California, San Francisco Bone Health and Osteoporosis Foundation University of Wisconsin–Madison

About

Anne E. de Papp is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, bone health, and osteoporosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	635
2	Public Health	2	2	343
3	Engineering	1	1	76
4	Natural Sciences	1	1	69
5	Biochemistry	1	1	69

Anne E. de Papp

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Prevalence of Vitamin D Inadequacy among Postmenopausal North American Women Receiving Osteoporosis Therapy Michael F. Holick, Ethel S. Siris, Neil Binkley, The Journal of Clinical Endocrinology & Metabolism	2005	888
Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study Clifford J. Rosen, Marc C. Hochberg, Sydney Lou Bonnick, Journal of Bone and Mineral Research	2005	337
Prevalence of Vitamin D Inadequacy Among Postmenopausal North American Women Receiving Osteoporosis Therapy Michael F. Holick, Ethel S. Siris, Neil Binkley, Obstetrical & Gynecological Survey NutritionGynecologyOsteoporosisBone DiseaseVitamin D Inadequacy	2005	242
A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover Andrew J. Burghardt, Galateia J. Kazakia, Miki Sode, Journal of Bone and Mineral Research	2010	235
Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate<i>Versus</i>Risedronate Over Two Years Sydney Lou Bonnick, Kenneth G. Saag, Douglas P. Kiel, The Journal of Clinical Endocrinology & Metabolism	2006	144
In Vivo Determination of Bone Structure in Postmenopausal Women: A Comparison of HR-pQCT and High-Field MR Imaging Galateia J. Kazakia, Benedict Hyun, Andrew J. Burghardt, Journal of Bone and Mineral Research	2007	136
Bone Density, Turnover, and Estimated Strength in Postmenopausal Women Treated With Odanacatib: A Randomized Trial Kim Brixen, Roland Chapurlat, Angela M. Cheung, The Journal of Clinical Endocrinology & Metabolism	2013	122
A cross-sectional study of bone turnover markers in healthy premenopausal women Anne E. de Papp, Henry G. Bone, Michael P. Caulfield, Bone Bone Turnover MarkersBone HealthReproductive HealthGynecologyMaternal Health	2007	101
Tolerability of Once-Weekly Alendronate in Patients With Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Study Susan L. Greenspan, Ellen Field-Munves, Richard P. Tonino, Mayo Clinic Proceedings Bone DiseaseBone HealthOnce-weekly AlendronatePlacebo-controlled StudyBone Density	2002	94
Short-term in vivo precision of BMD and parameters of trabecular architecture at the distal forearm and tibia Klaus Engelke, B. Stampa, Wolfram Timm, Osteoporosis International MechanobiologyEngineeringTrabecular ArchitectureVivo PrecisionBiomechanics	2011	76

Page 1